Beta-thalassemia major

For HBB c.118C>T (p.Gln40Ter), ex vivo BCL11A enhancer editing is a credible therapeutic route because it is variant-agnostic and can reduce the transfusion burden without directly repairing the stop codon. For a classic beta-zero allele like p.Gln40Ter, the strongest current editing logic is fetal-hemoglobin reactivation rather than bespoke correction of the HBB coding change.

ClinVar lists c.118C>T as pathogenic, and the variant is consistent with a severe loss-of-function beta-thalassemia mechanism. Exagamglogene autotemcel (Casgevy) received FDA approval for transfusion-dependent beta thalassemia in January 2024, and the phase 3 CLIMB THAL-111 study published in NEJM showed that most treated patients achieved transfusion independence through BCL11A erythroid enhancer editing. Because this platform edits autologous hematopoietic stem cells upstream of fetal-hemoglobin regulation, it is applicable across many severe HBB genotypes, including nonsense alleles such as p.Gln40Ter.

This is still intensive therapy: busulfan conditioning, stem-cell collection, specialized manufacturing, and prolonged follow-up are all required. The evidence is genotype-agnostic rather than specific to p.Gln40Ter, and outcomes can vary with baseline iron burden, marrow reserve, and genotype combinations on the second HBB allele. This approach also does not restore native adult beta-globin production; it compensates through fetal hemoglobin induction, so residual anemia and long-term durability still need continued surveillance.

For HBB c.92+5G>C, a splicing variant that abolishes beta-globin production, ex vivo CRISPR/Cas9 editing of the erythroid-specific BCL11A enhancer remains the clearest gene-editing fit because it reactivates fetal hemoglobin without needing to repair the HBB splice junction directly.

ClinVar lists c.92+5G>C as pathogenic for transfusion-dependent beta-thalassemia. Exagamglogene autotemcel (Casgevy) disrupts the BCL11A erythroid enhancer in autologous CD34+ cells and has shown durable transfusion independence in Phase 3 CLIMB THAL-111/121 trials, providing clinical proof that editing upstream fetal-hemoglobin regulators can offset severe HBB alleles (PMID:38657265; PMID:38661449). Additional long-term follow-up data document sustained HbF levels >30% and substantial iron-storage improvements, highlighting that the editing logic is allele-agnostic even for splice-site mutations such as c.92+5G>C.

Conditioning toxicity, manufacturing complexity, and the cost of ex vivo editing remain gatekeepers. The evidence is disease-level rather than variant-specific, so response may still vary with co-inherited HBB alleles and iron burden. Off-target editing, while low in current studies, still requires long-term surveillance and centralized follow-up. Treat this as a strong gene-editing platform argument for splice-disrupting HBB variants rather than a direct efficacy dataset for c.92+5G>C.

Base Editing (ABE8e) via RNP electroporation (ex vivo) delivery is a rationale-driven therapeutic strategy for Beta-thalassemia major targeting the HBB c.79G>A (p.Glu27Lys) variant (Pathogenic, missense variant). The editing system (ABE8e-nSpCas9 (adenine base editor)) converts the pathogenic A back to G on the target strand, restoring the wild-type codon. Target tissue: Blood/HSC. Therapeutic goal: Correct pathogenic HBB alleles and/or disrupt BCL11A erythroid enhancer to restore effective beta-globin or fetal hemoglobin expression and achieve transfusion independence in beta-thalassemia major.. Risk profile: off-target Medium (bystander bases in editing window), delivery complexity Medium, immunogenicity Low.

1. Molecular basis: HBB NM_000518.5(HBB):c.79G>A (p.Glu27Lys) is classified as Pathogenic (ClinVar variation ID 3777010). Molecular consequence: missense variant. Protein change: E27K, V24F. 2. Epidemiology: Approximately 60,000 symptomatic beta-thalassemia births annually worldwide, with highest prevalence in the Mediterranean, Middle East, South and Southeast Asia; beta-thalassemia major presents in infancy with severe anemia and is universally transfusion-dependent without curative therapy. 3. Standard of care: Lifelong regular red blood cell transfusions plus iron chelation; selected patients may receive allogeneic HSCT. Adjuncts include luspatercept to reduce transfusion burden. 4. Pipeline: Approved gene-addition (betibeglogene autotemcel) and gene-editing (exagamglogene autotemcel) therapies for transfusion-dependent beta-thalassemia; multiple Phase I/II/III trials of HbF inducers, small molecules, and next-generation gene-editing or gene-therapy approaches ongoing. 5. ABE clinical validation: ABE8e (Richter et al. 2020, Nat Biotechnol) achieves ~1.7x higher editing efficiency than ABE7.10. VERVE-101 demonstrated first-in-human LNP-ABE liver editing with 55-66% PCSK9 reduction (Raal et al. 2025, NEJM). Beam Therapeutics is advancing multiple ABE programs.

1. No published data specifically correcting HBB c.79G>A (p.Glu27Lys) with Base Editing (ABE8e); strategy is based on general principles and must be validated preclinically. 2. PAM availability and bystander base analysis for the specific genomic context have not been performed. If no canonical NGG PAM positions the target within the editing window, PAM-flexible variants (SpRY) may be needed. 3. Long-term durability, off-target genome-wide effects, and immunogenicity in the target patient population require thorough preclinical and clinical evaluation.